[1]
Dagher R, Helman L. Rhabdomyosarcoma: an overview. The oncologist. 1999:4(1):34-44
[PubMed PMID: 10337369]
Level 3 (low-level) evidence
[2]
Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui CH, Nichols KE, Downing JR. Germline Mutations in Predisposition Genes in Pediatric Cancer. The New England journal of medicine. 2015 Dec 10:373(24):2336-2346. doi: 10.1056/NEJMoa1508054. Epub 2015 Nov 18
[PubMed PMID: 26580448]
[3]
Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jul 10:27(20):3391-7. doi: 10.1200/JCO.2008.19.7483. Epub 2009 Apr 27
[PubMed PMID: 19398574]
[4]
Gallego Melcón S, Sánchez de Toledo Codina J. Rhabdomyosarcoma: present and future perspectives in diagnosis and treatment. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2005 Jan-Feb:7(1):35-41
[PubMed PMID: 15890156]
Level 3 (low-level) evidence
[5]
Ognjanovic S, Carozza SE, Chow EJ, Fox EE, Horel S, McLaughlin CC, Mueller BA, Puumala S, Reynolds P, Von Behren J, Spector L. Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype. British journal of cancer. 2010 Jan 5:102(1):227-31. doi: 10.1038/sj.bjc.6605484. Epub 2009 Dec 8
[PubMed PMID: 19997102]
[6]
Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Advances in anatomic pathology. 2013 Nov:20(6):387-97. doi: 10.1097/PAP.0b013e3182a92d0d. Epub
[PubMed PMID: 24113309]
Level 3 (low-level) evidence
[7]
Casanova M, Meazza C, Favini F, Fiore M, Morosi C, Ferrari A. Rhabdomyosarcoma of the extremities: a focus on tumors arising in the hand and foot. Pediatric hematology and oncology. 2009 Jul-Aug:26(5):321-31. doi: 10.1080/08880010902964367. Epub
[PubMed PMID: 19579078]
[8]
Khosla D, Sapkota S, Kapoor R, Kumar R, Sharma SC. Adult rhabdomyosarcoma: Clinical presentation, treatment, and outcome. Journal of cancer research and therapeutics. 2015 Oct-Dec:11(4):830-4. doi: 10.4103/0973-1482.144637. Epub
[PubMed PMID: 26881526]
[9]
Kashi VP, Hatley ME, Galindo RL. Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nature reviews. Cancer. 2015 Jul:15(7):426-39. doi: 10.1038/nrc3961. Epub
[PubMed PMID: 26105539]
Level 3 (low-level) evidence
[10]
Esnaola NF, Rubin BP, Baldini EH, Vasudevan N, Demetri GD, Fletcher CD, Singer S. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Annals of surgery. 2001 Aug:234(2):215-23
[PubMed PMID: 11505068]
[11]
Gerber NK, Wexler LH, Singer S, Alektiar KM, Keohan ML, Shi W, Zhang Z, Wolden S. Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols. International journal of radiation oncology, biology, physics. 2013 May 1:86(1):58-63. doi: 10.1016/j.ijrobp.2012.12.016. Epub 2013 Feb 13
[PubMed PMID: 23414767]
[12]
Ogilvie CM, Crawford EA, Slotcavage RL, King JJ, Lackman RD, Hartner L, Staddon AP. Treatment of adult rhabdomyosarcoma. American journal of clinical oncology. 2010 Apr:33(2):128-31. doi: 10.1097/COC.0b013e3181979222. Epub
[PubMed PMID: 19770626]
[13]
Winter S, Fasola S, Brisse H, Mosseri V, Orbach D. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy. Pediatric blood & cancer. 2015 Nov:62(11):1935-41. doi: 10.1002/pbc.25622. Epub 2015 Jul 6
[PubMed PMID: 26150380]
[14]
Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, Carli M, Anderson JR. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 May 10:26(14):2384-9. doi: 10.1200/JCO.2007.14.7207. Epub
[PubMed PMID: 18467730]
[15]
Liu YT, Wang CW, Hong RL, Kuo SH. Prognostic Factors and Treatment Outcomes of Adult Patients With Rhabdomyosarcoma After Multimodality Treatment. Anticancer research. 2019 Mar:39(3):1355-1364. doi: 10.21873/anticanres.13249. Epub
[PubMed PMID: 30842169]
[16]
Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, Barr FG, Hawkins DS. Rhabdomyosarcoma. Nature reviews. Disease primers. 2019 Jan 7:5(1):1. doi: 10.1038/s41572-018-0051-2. Epub 2019 Jan 7
[PubMed PMID: 30617281]